Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non-muscle-invasive Bladder Cancer.
Beijert IJ, Hagberg O, Gårdmark T, Holmberg L, Häggström C, Johnston A, Trail M, Hamid S, Dreyer BA, Padovani L, Garau R, Hasan R, Ahmad I, Hendry D, Compérat EM, Burger M, Rouprêt M, Gontero P, Ribal MJ, van der Kwast TH, Babjuk M, Sylvester RJ, Mariappan P, Liedberg F, van Rhijn BWG; BladderBaSe-Consortium; Scot BC Quality OPS Collaborative; Multi-center EAU Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study Consortium on the WHO1973; WHO2004/2016 Classification Systems for Grade. Beijert IJ, et al. Among authors: gontero p. Eur Urol. 2024 Nov;86(5):391-399. doi: 10.1016/j.eururo.2024.08.013. Epub 2024 Aug 29. Eur Urol. 2024. PMID: 39209674 Free article.
Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Oddens J, et al. Among authors: gontero p. Eur Urol. 2013 Mar;63(3):462-72. doi: 10.1016/j.eururo.2012.10.039. Epub 2012 Nov 2. Eur Urol. 2013. PMID: 23141049 Clinical Trial.
Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.
Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, Gontero P, Chun FK, Fisch M, Scherr DS, Shariat SF. Kluth LA, et al. Among authors: gontero p. World J Urol. 2013 Oct;31(5):1029-36. doi: 10.1007/s00345-012-0996-9. Epub 2012 Nov 30. World J Urol. 2013. PMID: 23196773
Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.
Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Brausi M, et al. Among authors: gontero p. Eur Urol. 2014 Jan;65(1):69-76. doi: 10.1016/j.eururo.2013.07.021. Epub 2013 Jul 24. Eur Urol. 2014. PMID: 23910233 Clinical Trial.
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. Gontero P, et al. Eur Urol. 2015 Jan;67(1):74-82. doi: 10.1016/j.eururo.2014.06.040. Epub 2014 Jul 16. Eur Urol. 2015. PMID: 25043942 Free article.
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J. Cambier S, et al. Among authors: gontero p. Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23. Eur Urol. 2016. PMID: 26210894 Clinical Trial.
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.
Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmström PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. Gontero P, et al. BJU Int. 2016 Jul;118(1):44-52. doi: 10.1111/bju.13354. Epub 2015 Nov 6. BJU Int. 2016. PMID: 26469362 Free PMC article.
Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9.
Sylvester R, Gontero P, Oddens J. Sylvester R, et al. Among authors: gontero p. Eur Urol. 2016 Jun;69(6):e123-4. doi: 10.1016/j.eururo.2016.01.055. Epub 2016 Feb 10. Eur Urol. 2016. PMID: 26874805 No abstract available.
566 results